SARAH CARTER: Open Payments
NPI 1528532603 · UPLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$796 in 41 payments from 12 companies in 2025. Trend: 2023 $1,239 · 2024 $863 · 2025 $796
Food & beverage: $796
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $181 |
| E.R. Squibb & Sons, L.L.C. | 8 | $155 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $113 |
| Alkermes, Inc. | 2 | $66 |
| Janssen Pharmaceuticals, Inc | 3 | $61 |
| Almatica Pharma LLC | 2 | $50 |
| ABBVIE INC. | 3 | $46 |
| Luye Pharma (USA) Ltd. | 2 | $39 |
| Neurocrine BioSciences, Inc. | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: REXULTI, COBENFY, CAPLYTA, ARISTADA, INVEGA SUSTENNA, LOREEV XR, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across CA — which companies pay providers there.
